Navigation Links
Streck-CN free Lyse CD Lytic Reagent

ProductsStreck-CN free Lyse CD Lytic Reagent
Company Streck
Item Streck-CN free Lyse CD Lytic Reagent
Features 
Description An environmentally-safe, CN-free lytic reagent designed for use on the Abbott CELL-DYN® 1800 three-part differential hematology analyzer.
Info Streck
Customer Service: (800) 228-6090
Web site: http://www.streck.com/default.asp

Related medicine products :

1. Streck-CD3500 Hemoglobin/Lyse Lytic Reagent
2. Streck-Hemoglobin/Lyse Lytic Reagent
3. Streck-Lysing Agent III Lytic Reagent
4. Streck-Lysing Agent IIIC Lytic Reagent
5. Streck-Lysing Agent IIIA Lytic Reagent
6. Bilirubin Direct Reagent
7. Bilirubin Total Reagent
8. Direct Bilirubin Reagent
9. Total Bilirubin Reagent
10. BUN Liquidplus Reagent
11. BUN Rate Reagent
Smooth colibri tip used to grasp and subsequently retract the capsule during nucleus delivery. Serrated handle with polished finish.
Tennant straight tying forceps, 6.0 mm tying platforms, with pin, extra delicate smooth jaws.
O'Gawa-Castroviejo tying forceps, straight shafts, 6 mm tying platforms, wide handle.
Hatsis tying forceps, titanium, long thin tying platforms.
Medicine Products:
(Date:1/8/2009)...ilable that work, CDC officials stress , ...ommon strain of flu this season is resistant to th...ealth officials said Thursday there is no reason t...has been slow, and that other drugs work well agai...s adopting a watchful attitude for now. , While...
(Date:1/8/2009)...e/ -- A study released this week showing that a gr...ple chronic diseases shines a much-needed spotligh... to one that focuses on primary and secondary prev... leader in disease prevention. , , (Logo: h...9LOGO ) , , The study, conducted by Social &a...
(Date:1/8/2009)...vealed Friday, January 9 , , WASHINGTON, Jan. ...yees International Union (SEIU) President Andy Ste...ional Executive Board to discuss the forced transf... of SEIU United Healthcare Workers-West (UHW), its...cision until tomorrow. , , According to reports...
(Date:1/8/2009)...r Tom Torlakson Introduces AB 89 , , SACRAMENTO...y, Lung Cancer Alliance-California (LCA-CA), haile... District) for his continued leadership in introdu... research. For the third consecutive year, legisl...g considered in the California Legislature. , ...
Breaking Medicine News(10 mins):Health News:Common Flu Strain Resistant to Popular Antiviral Drug 2Health News:Common Flu Strain Resistant to Popular Antiviral Drug 3Health News:U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention 2Health News:SEIU Decision to Force Transfer of Long-Term Care Members Out of United Healthcare Workers Delayed 2Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2
...chives of Diseases in Childhood has shown that chi...avioural problems at age 14. Obesity starts from c...an increase risk of diabetes and cardiovascular di...s of body size with psychological distress have b...
...sion and even prolong it. people who suffer from l...m mental disease than people who sleep soundly. In...of the Associated Professional Sleep Societies (AP...f Rochester Sleep and Neurophysiology Research Lab...
...more and more common as women are opting for a car...and pushing motherhood to mid thirties, late thirt... it it’s own source of woes and risks to the mothe...d to the existent risk factors, poor health of the...
...was found that older women suffering from chronic ...- acquired early in life) were found to have more ... did not have the infection. This was reported in ...his is the first time an association between CMV a...
Other Medicine News:
(Date:1/7/2009)... FREDERICK, Md., Jan. 7 ImQuest Li...ion of an IND application to the Food and Drug Adm...their lead pyrimidinedione HIV inhibitor IQP-0410....ies in the first quarter of 2009. IQP-0410 is a no...y acts as a nonnucleoside reverse transcriptase in...
(Date:1/6/2009)... Program Expands on Successful Results from prior ... 7 Vital Therapies, Inc. (VTI), a ... today announced patient enrollment has begun for ...inical trial that will study the Extracorporeal Li...ts with Acute Liver Failure (ALF) under three prot...
(Date:1/6/2009)... ROCKVILLE, Md., Jan. 6 ...l company focused on diseases of epidemic potentia...date for the treatment of tuberculosis (TB), was t...warded clinical program contract to Dynport Vaccin...tract, awarded by the National Institute of Allerg...
(Date:1/5/2009)... SAN DIEGO, Jan. 5 Cylene Pharmace...ase I clinical trial of its oral CK2 protein kinas...lid tumors, Castleman,s disease, or multiple myelo...ing trial are determination of safety, tolerance a...opriate dose for Phase II trials. In addition, mul...
Breaking Medicine Technology:ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3Kyphon Announces Special Meeting Date to Vote on Proposed Medtronic Merger 742 1Kyphon Announces Special Meeting Date to Vote on Proposed Medtronic Merger 742 2Kyphon Announces Special Meeting Date to Vote on Proposed Medtronic Merger 742 3ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB 402 421 1ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB 402 421 2ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB 402 421 3ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB 402 421 4ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB 402 421 5Cipla Tell the Truth 3B AIDS Healthcare Foundation Launches New Ad Campaign 739 1Cipla Tell the Truth 3B AIDS Healthcare Foundation Launches New Ad Campaign 739 2Cipla Tell the Truth 3B AIDS Healthcare Foundation Launches New Ad Campaign 739 3Cipla Tell the Truth 3B AIDS Healthcare Foundation Launches New Ad Campaign 739 4Cipla Tell the Truth 3B AIDS Healthcare Foundation Launches New Ad Campaign 739 5Cipla Tell the Truth 3B AIDS Healthcare Foundation Launches New Ad Campaign 739 6Cipla Tell the Truth 3B AIDS Healthcare Foundation Launches New Ad Campaign 739 7Hospitals Agree to Pay Fees in Exchange for More Income but Consumers in the Dark About What Theyll be Charged Under Nunez Plan 736 1
..., N.J.--(BUSINESS WIRE)--Jun 28, 2007,- Progenics ...rmaceuticals, a division of Wyeth (NYSE: WYE), tod...pen-label extension study of,subcutaneous methylna...ipation (OIC) in patients with advanced illness. T...ltinational Association of,Supportive Care in Canc...
...IRE)--Jun 28, 2007 - CombinatoRx,Incorporated (NA...,its randomized, blinded, placebo-controlled clini...rthritis (RA). The trial,compared CRx-150 plus a d...acebo plus DMARD (control) in subjects with active...x-150 demonstrated,statistically significant effec...
Other Medicine Technology:Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 2Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 3Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 4Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 5Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 6CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 2CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 3CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 4CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 5